Dietary Intake of a Plant Phospholipid/Lipid Conjugate Reduces Lung Cancer Growth and Tumor Angiogenesis
Menée sur un modèle murin de carcinome pulmonaire de Lewis, cette étude montre que la consommation de composés phospholipidiques ou lipidiques d'origine végétale peut réduire la croissance et l'angiogenèse tumorales
Résumé en anglais
It is well recognized that early detection and cancer prevention are significant armaments in the “war against cancer”. Changes in lifestyle and diet have significant impact on the global incidence of cancer. For over 30 years many investigators have studied the concept of chemoprevention. More recently, with the demonstration that anti-angiogenic activity reduces tumor growth, the concept of angioprevention has emerged as a novel strategy in the deterrence of cancer development (carcinogenesis). In the present study, we utilized a fast growing, highly aggressive murine Lewis lung cancer model to examine the in vivo anti-tumor effects of a novel, dietary supplement, known as plant phospholipid/lipid conjugate (pPLC). Our goal was to determine if pPLC possessed direct anti-tumor activity that because of relatively little toxicity could be developed as a chemoprevention therapy. We used pPLC directly in this in vivo model due to the lack of aqueous solubility of this novel formulation, which precludes in vitro experimentation. pPLC contains known anti-oxidants, ferulic acid and lipoic acid, as well as soy sterols, formulated in a unique aqueous-insoluble matrix. The pPLC dietary supplement was shown to suppress in vivo growth of this tumor model by 30%. We also demonstrated a significant decrease in tumor angiogenesis accompanied by increased apoptosis, and present preliminary evidence of enhanced expression of the hypoxia-related genes pentraxin-3 and metallothionein-3, by 24.9- and 10.9-fold, respectively, compared with vehicle control. These findings lead us to propose using this plant phosolipid/lipid conjugate as a dietary supplement that maybe useful in cancer prevention.
